Paper - WANFANG MED ONLINE

You Position: Home > Paper

Experts proposal on combination therapy of nucleos(t)ide analogues for chronic hepatitis B

( views:727, downloads:552 )

Author:: No author available

Journal Title:: CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES

Issue:: 2

DOI:: 10.3760/cma.j.issn.1674-2397.2011.02.001

Key Word:: 肝炎,乙型,慢性;核苷(酸)类药物;联合治疗;Chronic hepatitis B;Nucleos(t)ide analogues;Combination therapy

Abstract： @@ 随着核苷(酸)类药物(NAs)在慢性乙型肝炎(CHB)治疗中的广泛应用和深人研究,各级临床医师意识到NAs单药治疗不能解决所有问题,主要表现在出现应答不佳、耐药及难以通过短期治疗实现停药和获得持久应答等.

Reference

[1]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）[J].2011,(1).
[2]贾红宇,卢微,郑临,等.拉米夫定单药及其初始联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化的疗效比较[J].2011,(2).
[3].拉米夫定优化治疗慢性乙型肝炎专家会议纪要[J].2009,(2).
[4]喻剑华,施军平,武静,等.拉米夫定和阿德福韦酯初始联合与恩替卡韦单药治疗慢性乙型肝炎的疗效和安全性比较[J].2011,(2).
[5]董菁,成军,王勤环,等.慢性乙型肝炎患者体内乙型肝炎病毒准种特点的初步研究[J].2001,(4).
[6]Xiong S,Yang H,Delaney WE 4th,etc.Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro.[J].2004,48(10).
[7]Lee SJ,Joo MK,Kim JH.Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.[J].2009,54(7).
[8]European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B[J].2009,50(2).
[9]Lee HW,Lee HJ,Hwang J.Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.[J].2010,51(2).
[10]Ghany MG,Doo EC.Antiviral resistance and hepatitis B therapy.[J].2009,49(5 Suppl.).
[11]Chen L,Yu JL,Gong QM,etc.Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.[J].2011,60(9).
[12]Kim DH,Bang SJ,Park NH,etc.Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.[J].2005,12(4).
[13]Lok AS,McMahon BJ.Chronic hepatitis B: update 2009.[J].2009,50(3).
[14]Kim KM,Shim JH,Suh DJ.Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.[J].2009,50(4).
[15]Locarnini S,Zoulim F.Hepatitis B virus resistance to nucleos(t)ide analogues.[J].2009,137(5).
[16]Zeuzem S,Gane E,Liaw YF.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.[J].2009,51(1).
[17]Lange CM,Bojunga J,Hofmann W.Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.[J].2009,50(6).
[18]Esteban-Mur R,Koff RS,Gane EJ,etc.Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.[J].2007,5(8).